Welcome reception

Introduction & Meeting Objectives
John Gribben

Session 1:  T-cell lymphoma

Chairs: Laurence de Leval & Francine Foss

• Genomic profiling for clinical decision making in TCL: Laurence de Leval
• Translational discovery in PTCL: Giorgio Inghirami
• 5-azacitidine in follicular helper T-cell lymphomas: François Lemonnier
• Therapeutic options for the treatment of PTCLs: Francine Foss
• Targeting signaling pathways in T-cell lymphoma: Steven Horwitz

Panel Discussion

Break

Session 2:  Evolving frontline immune-chemotherapy for MCL and the impact on survival outcomes                                                                                       
Chairs: Stephen Ansell & Elaine Jaffa

• Biological characteristics of high-risk MCL: Eric Hsi
• Significance of the TRIANGLE trial for MCL: Marek Trněný
• Future role of ASCT in MCL: John Kuruvilla
• Do you need to treat young and old MCL patients differently? Stephen Ansell
• Novel agents for relapsed MCL: Yucai Wang
• ViPOR regimen in MCL: Wyndham Wilson

Panel Discussion: Remaining gaps and perspectives

Session 3: Keynote address
Chair & Introduction: Andreas Rosenwald

• Emerging role of super-enhancer hypermutation deregulating gene expression
  in DLBCL – pathogenetic and therapeutic implications: Riccardo Dalla-Favera

Panel Discussion

Lunch

Session 4: New pathogenetic mechanisms and therapeutic targets in DLBCL
Chairs: Riccardo Dalla-Favera & Ash Alizadeh

• Molecular pathogenesis of germinal center-derived B-cell lymphomas: Laura Pasqualucci
• Genomic alterations in DLBCL – new relevant pathways and potential therapeutic targets:
  Ken Young
• Cell-free DNA – mutations for MRD monitoring & epigenetics/fragmentomics for disease detection in various lymphomas: Ash Alizadeh

Panel Discussion

Break

Session 4: Novel Therapies Part 1
Chairs:  John Gribben & Laurie Sehn

• Novel drug development: an industry perspective; Simon Rule
  

Industry Panel Discussion

Antibody-drug conjugates:

• POLARIX – Polatuzumab vedotin: Laurie Sehn
• Zilovertamab: Sven De Vos
• Loncastuximab tesirine: Paolo Caimi
• Camidanlumab: Andrew Davies
• Brentuximab vedotin: Stephen Ansell
• Emerging ADCs with novel targets: Juan Pablo Alderuccio

Menin inhibitors

• BMF-219: Paolo Caimi

 Panel Discussion

Day 1 summary

Session 6: Expanding the CAR platform for NHL
Chairs: David Maloney & Jason Westin

• Tisa-cel; Stephen Schuster
• Axi-cel; Sattva Neelapu
• Liso-cel; David Maloney
• C-CAR066 & C-CAR039; John Gerecitano
• Expanding to T cell lymphomas; LaQuisa Hill
• CB-010: CD19-directed, PD-1 KO, AlloCAR for R/R B-cell lymphomas; James Essell

Panel Discussion (15 min)

• Repeat CAR-T following failure of a first CD19 CAR-T – does it work?: David Miklos
• Expanding CAR T-cells as a second-line therapy for LBCL – A paradigm shift?: Jason Westin
• Allogeneic CAR-T for NHL – fact or fantasy?: Tanya Siddiqi
• CAR T-cell therapy in the ‘real world’; Lazaros Lekakis
• Long-term outcomes following CAR-T cell therapy – what do we know so far? James Kochenderfer

Panel Discussion: CAR-T in the real-World Setting

Break

Session 7: Novel Therapies Part 2: BTK inhibitors
Chairs:  Laurie Sehn & Tanya Siddiqi

• Ibrutinib combinations in younger lymphoma patient; Wyndham Wilson
• Zanubrutinib; Mazyar Shadman
• Acalabrutinib; Marek Trněný
• Pirtobrutinib; Nirav Shah
• BTK Degraders – NX-2127; Tanya Siddiqi

Panel Discussion

Lunch

Session 8: Bispecifics for NHL
Chairs: Martin Hutchings & Marion Subklewe

• CD20/CD3 bispecific antibodies – how to choose? Mazyar Shadman
• Glofitamab; Martin Hutchings
• Mosunetuzumab; Laurie Sehn
• Blinatumomab; Marion Subklewe

Roundtable Discussion

• Plamotamab; Krish Patel
• Odronextamab; Krish Patel
• TNB 486; Ranjit Nair
• Epcoritamab; Martin Hutchings

Roundtable Discussion                        

Closing remarks
John Gribben